Haleon plc
Haleon plc Q1 FY26 Results — Earnings Call Analysis
Q1 FY26 earnings call: what management said on revenue, margins and capex.
What the Q1 FY26 call signalled
1 of 3 strong
The short version
- Organic sales growth guidance for 2026 is 3% to 5%, signaling some sequential acceleration from 3% in 2025. - Haleon expects to return to growth in 2026, with the U.S.
From Haleon plc's Q1 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- Organic sales growth guidance for 2026 is 3% to 5%, signaling some sequential acceleration from 3% in 2025.
- Medium-term ambition remains 4% to 6% growth, supported by expected stronger performance in North America and continued strength in emerging markets.
- Volume growth is a focus, with a target price-volume mix split around 60-40 in favor of volume, especially from Asia Pacific (80% volume-driven growth).
- Key drivers include shelf resets, distribution gains, and commercial activations planned in 2026, particularly in the U.S. market.
- Innovation and increased investment in Advertising & Promotion (A&P) and R&D support growth expectations.
2 more points from Haleon plc's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Haleon plc said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company is focusing on investing at a healthy level of 20.5% of sales, emphasizing sustainable growth.
- Increased A&P (advertising and promotion) spend by 7.5% and R&D by 7.7% to support brand growth, especially in Oral Health and emerging markets.
- Investments are directed towards digital media (60% of working media) to balance legacy and digital marketing.
- Significant investment in supply chain productivity programs, focusing on reducing complexity (e.g., packaging harmonization) and operational efficiency (e.g., reducing formulations to increase capacity).
- Increased the sales force and field force engagement, including bringing sales forces in-house in countries like India to expand reach.
2 more points from Haleon plc's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Haleon plc said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Haleon plc said on order book & pipeline — free account, 30 seconds.
Continue your research
Others in Pharmaceuticals this season
- Takeda Pharmaceutical Company Limited (Q1 FY26)
Takeda Pharmaceutical Company Limited Q1 FY26 quarterly results analysis. Growth in plasma-derived therapies (PDT) expected to be mid-single-digit growth for th
- Novo Nordisk A/S (Q1 FY26)
Novo Nordisk A/S Q1 FY26 quarterly results analysis. 2026 sales growth is expected to be negative, with adjusted sales growth projected at -5% to -13% at consta
- Sanofi (Q1 FY26)
Sanofi Q1 FY26 quarterly results analysis. For 2026, Sanofi expects sales to grow by a high single-digit percentage and business EPS to grow slightly faster tha
- Novartis AG (Q1 FY26)
Novartis AG Q1 FY26 quarterly results analysis. Novartis expects low single-digit sales growth in 2026 despite significant patent expiries and generic competiti
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Haleon plc and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Haleon plc Q1 FY26 results?
- Organic sales growth guidance for 2026 is 3% to 5%, signaling some sequential acceleration from 3% in 2025. - Haleon expects to return to growth in 2026, with the U.S.
What is Haleon plc share price analysis?
Haleon plc currently shows a neutral. The stock trades at a P/E of 18.5 with a market cap of $41,014. Investors should review the full earnings analysis for detailed insights.
Is Haleon plc planning capital expenditure?
- The company is focusing on investing at a healthy level of 20.5% of sales, emphasizing sustainable growth.
Keep Haleon plc on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.